Tropé Lectures – Updates and controversies in gynecologic oncology

Dr Yun Wang, principal investigator in the RAD-18-001 study in ovarian cancer, will  present at the Norwegian Radium Hospital and Memorial Sloan Kettering Meeting “Updates and Controversies in Gynecological Oncology”.

In the lecture titled “Novel radiopharmaceutical for peritoneal recurrence in ovarian cancer”, safety data from the dose escalation cohort when all patients had completed at least 12 months follow up, will be presented.

Organiser: Norwegian Radium Hospital and Memorial Sloan Kettering
Venue:

The auditorium in Building K
Institute for Cancer Research,
The Norwegian Radium Hospital
Oslo, Norway

 


Date: 24 May 2024
Program:

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent ASA Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close